Effects of myakuryu on hemorheological characteristics and mesenteric microcirculation of rats fed with a high-fat diet.
There is evidence that hyperlipidemia can induce hemorheological and microcirculatory disturbances. Myakuryu, a Chinese traditional medicine is efficacious in promoting lipid metabolism and protecting oxidative stress, but whether this drug can ameliorate rheologic disturbances caused by hyperlipidemia is still unknown. The present study was conducted to investigate the effects of myakuryu on hemorheological and microcirculatory disturbances induced by hyperlipidemia. Wistar rats were divided into a group on control diet (n=8) and a group on high-fat diet (HFD, n=44). Eight weeks later, plasma triglyceride (TG) and total cholesterol (TC) were determined. Sixteen animals with the highest levels of hyperlipidemia from the HFD group were randomly divided into two sub-groups: the untreated hyperlipidemia group (n=8) and the group treated with myakuryu (n=8). At the end of the sixteenth week, rheological and microcirculatory parameters were measured. Chemical analysis showed that myakuryu treatment caused significant reductions of plasma TG and TC levels (P<0.01), and the cholesterol/phospholipid ratio in the erythrocyte membrane (P<0.05). Rheological and microcirculatory measurements showed that myakuryu treatment led to a significant decrease in the erythrocyte aggregation index, plasma viscosity and blood viscosity at shear rates of 50, 100 and 150 s(-1) and in adherent leukocytes in mesenteric venules. There was a significant increase in erythrocyte deformation, electrophoretic mobility, membrane fluidity and F-actin content in the erythrocyte membrane as well as in red cell velocity in mesenteric venules. Our findings suggest that myakuryu treatment can improve blood flow and reduce adherent leukocytes in the venules of rats fed with HFD by ameliorating blood viscosity, erythrocyte deformability and aggregation, and other hemorheological characteristics.
Wang
Xian-Wei
XW
Department of Biophysics, Health Science Center, Peking University, Beijing, People's Republic of China.
Hu
Lin
L
Zeng
Zhu
Z
Yao
Wei-Juan
WJ
Han
Jing-Yan
JY
Zhang
Ying-Yu
YY
Xu
Xiao-Feng
XF
Liu
Yu-Ying
YY
Ka
Wei-Bo
WB
Sun
Da-Gong
DG
Wen
Zong-Yao
ZY
Chien
Shu
S
D000199:Actins / Q000097:blood; D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects; D001809:Blood Viscosity / Q000187:drug effects; D001835:Body Weight; D002448:Cell Adhesion / Q000187:drug effects; D004041:Dietary Fats / Q000008:administration & dosage; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004903:Erythrocyte Aggregation / Q000187:drug effects; D004910:Erythrocyte Membrane / Q000378:metabolism; D018056:Hemorheology / Q000187:drug effects*; D006949:Hyperlipidemias / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D007962:Leukocytes / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008560:Membrane Fluidity / Q000187:drug effects; D008642:Mesenteric Veins / Q000187:drug effects / Q000503:physiopathology; D008833:Microcirculation / Q000187:drug effects; D008517:Phytotherapy / Q000379:methods*; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D028321:Plant Preparations / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar
D000199:Actins; D004041:Dietary Fats; D008055:Lipids; C511309:Myakuryu; D010936:Plant Extracts; D028321:Plant Preparations